Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NVCR
stocks logo

NVCR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
166.60M
+3.31%
-0.430
-29.51%
166.59M
+7.48%
-0.423
+36.56%
170.38M
+7.29%
-0.413
+14.81%
Estimates Revision
The market is revising Upward the revenue expectations for NovoCure Limited (NVCR) for FY2025, with the revenue forecasts being adjusted by 2.83% over the past three months. During the same period, the stock price has changed by -4.23%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.83%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-12.66%
In Past 3 Month
Stock Price
Go Down
down Image
-4.23%
In Past 3 Month
Wall Street analysts forecast NVCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVCR is 28.40 USD with a low forecast of 18.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast NVCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVCR is 28.40 USD with a low forecast of 18.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 11.760
sliders
Low
18.00
Averages
28.40
High
42.00
Current: 11.760
sliders
Low
18.00
Averages
28.40
High
42.00
H.C. Wainwright
Buy
maintain
$38 -> $42
2025-10-30
Reason
H.C. Wainwright
Price Target
$38 -> $42
2025-10-30
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Novocure to $42 from $38 and keeps a Buy rating on the shares following the Q3 report. The company's lung sales were inline with expectations while a Japan approval could provide a turnaround in 2026, the analyst tells investors in a research note.
JPMorgan
Jessica Fye
Neutral
downgrade
$25 -> $23
2025-10-27
Reason
JPMorgan
Jessica Fye
Price Target
$25 -> $23
2025-10-27
downgrade
Neutral
Reason
JPMorgan analyst Jessica Fye lowered the firm's price target on Novocure to $23 from $25 and keeps a Neutral rating on the shares. The firm updated the company's model to reflect increased long-term conservatism.
Wells Fargo
Larry Biegelsen
Overweight -> Equal Weight
downgrade
$40
2025-07-24
Reason
Wells Fargo
Larry Biegelsen
Price Target
$40
2025-07-24
downgrade
Overweight -> Equal Weight
Reason
Wells Fargo analyst Larry Biegelsen downgraded Novocure to Equal Weight from Overweight with a price target of $14.50, down from $40.
Wells Fargo
Overweight -> Equal Weight
downgrade
$40
2025-07-24
Reason
Wells Fargo
Price Target
$40
2025-07-24
downgrade
Overweight -> Equal Weight
Reason
Wells Fargo downgraded Novocure to Equal Weight from Overweight with a price target of $14.50, down from $40. The company reported "disappointing" Q2 results, including softer glioblastoma scripts outside the U.S. and a slow ramp in lung cancer, the analyst tells investors in a research note. Meanwhile, the pact from yhr PANOVA-3 and METIS studies are more than 12 months out, the firm adds. Wells is positive on Optune longer term but does not catalysts to drive share outperformance over the next year.
Ladenburg
Kevin Degeeter
initiated
$30
2025-07-08
Reason
Ladenburg
Kevin Degeeter
Price Target
$30
2025-07-08
initiated
Reason
Ladenburg analyst Kevin Degeeter initiated coverage of Novocure with a Buy rating and $30 price target.
Ladenburg
NULL -> Buy
initiated
$30
2025-07-08
Reason
Ladenburg
Price Target
$30
2025-07-08
initiated
NULL -> Buy
Reason
As previously reported, Ladenburg initiated coverage of Novocure with a Buy rating and $30 price target. The firm cites a positive outlook for Optune Gio to retain "healthy market share" in glioblastoma, a path to profitability based on uptake of Optune Lua in treatment of second-line non small cell lung cancer and evidence supporting Tumor Treating Fields as a platform technology for various solid tumors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Novocure Ltd (NVCR.O) is -8.00, compared to its 5-year average forward P/E of -4.63. For a more detailed relative valuation and DCF analysis to assess Novocure Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.63
Current PE
-8.00
Overvalued PE
432.75
Undervalued PE
-442.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-121.12
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
221.42
Undervalued EV/EBITDA
-463.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
11.91
Current PS
0.00
Overvalued PS
21.95
Undervalued PS
1.87
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 330.05% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 330.05% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NVCR News & Events

Events Timeline

(ET)
2025-12-01
07:19:00
Novocure Appoints Frank Leonard as CEO Effective Immediately
select
2025-10-30 (ET)
2025-10-30
08:02:38
Novocure Announces Q3 Earnings Per Share of 33 Cents, Below Consensus Estimate of 42 Cents
select
2025-09-29 (ET)
2025-09-29
16:32:13
Novocure to Showcase Final Findings from Key Phase 3 METIS Trial at ASTRO
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-01Newsfilter
Novocure Appoints Frank Leonard as CEO, Effective Immediately
  • Leadership Change: Novocure has appointed Frank Leonard as CEO effective immediately, succeeding Ashley Cordova, with Frank bringing over 15 years of experience in various leadership roles that have driven the global operations of the company's unique device-based cancer therapies.
  • Strategic Development: During his tenure as President, Frank oversaw global sales, marketing, and product strategy functions, successfully preparing the company for its first commercial launch, highlighting his critical role in driving the company's growth.
  • Patient-Centric Mission: Frank emphasized that patients are at the core of Novocure's work, committing to extend survival for patients with the most aggressive cancers, indicating a continued focus on leveraging innovative therapies.
  • Future Outlook: Under Frank's leadership as CEO, Novocure plans to launch products in new indications and complete multiple clinical trials, further advancing the commercialization of its innovative therapies.
[object Object]
Preview
5.0
12-01NASDAQ.COM
Novocure's CEO Ashley Cordova Steps Down; Frank Leonard Appointed as Successor
  • CEO Resignation: Ashley Cordova has resigned as CEO of NovoCure Ltd., a Swiss medical devices and healthcare company.
  • New Leadership: Frank Leonard, who has been with NovoCure since 2010, has been appointed as the new CEO, effective immediately.
  • Company Background: Leonard has held various leadership roles within the company, including in sales, marketing, and product strategy.
  • Stock Performance: Following the announcement, NovoCure's shares were trading at $12.61, reflecting a 1.56% decrease on the Nasdaq.
[object Object]
Preview
5.0
12-01SeekingAlpha
Frank Leonard Appointed as CEO of Novocure

  • New CEO Appointment: Novocure has appointed Frank Leonard as the new chief executive officer, effective immediately, succeeding Ashley Cordova who has resigned.

  • Company Performance: Novocure's stock is down 1.48% in premarket trading, reflecting market reactions to the leadership change.

  • Future Plans: The company has outlined a four-indication expansion and a profitability target for 2027, focusing on growth in glioblastoma (GBM) treatments.

  • Earnings Call Insights: Novocure is preparing for its Q3 2025 earnings call, where it will discuss its performance and future strategies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Novocure Ltd (NVCR) stock price today?

The current price of NVCR is 11.76 USD — it has decreased -0.42 % in the last trading day.

arrow icon

What is Novocure Ltd (NVCR)'s business?

NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.

arrow icon

What is the price predicton of NVCR Stock?

Wall Street analysts forecast NVCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVCR is 28.40 USD with a low forecast of 18.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Novocure Ltd (NVCR)'s revenue for the last quarter?

Novocure Ltd revenue for the last quarter amounts to 167.20M USD, increased 7.81 % YoY.

arrow icon

What is Novocure Ltd (NVCR)'s earnings per share (EPS) for the last quarter?

Novocure Ltd. EPS for the last quarter amounts to -0.33 USD, increased 17.86 % YoY.

arrow icon

What changes have occurred in the market's expectations for Novocure Ltd (NVCR)'s fundamentals?

The market is revising Upward the revenue expectations for NovoCure Limited (NVCR) for FY2025, with the revenue forecasts being adjusted by 2.83% over the past three months. During the same period, the stock price has changed by -4.23%.
arrow icon

How many employees does Novocure Ltd (NVCR). have?

Novocure Ltd (NVCR) has 1488 emplpoyees as of December 05 2025.

arrow icon

What is Novocure Ltd (NVCR) market cap?

Today NVCR has the market capitalization of 1.32B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free